News

Under the contract HGS will manufacture and deliver 20,000 treatment courses of the compound, Abthrax, to the strategic national stockpile. The company will also complete the additional laboratory

Currently Nutra Pharma owns 38.1% of ReceptoPharm. The merger will provide Nutra Pharma with 100% of the outstanding ReceptoPharm stock and complete ownership of the ReceptoPharm intellectual property.

The phase II study will explore the safety of Varisolve in 50 patients who have a patent foramen ovale (PFO), a defect estimated to be present in approximately

The study, which has enrolled a total of 31 returning patients from a previous trial and 54 new patients, will examine IR103, a second generation immunotherapy, as a

These experiments showed that at the highest level of dosing required by the FDA in preclinical studies, levels of the active compound exceeded 50,000 times the EC50 for

Specifically, the results indicate that a proportion of patients receiving eight weeks of treatment with VGV-1 and no additional anti-HIV therapy experienced a decrease in viral load at

The first study, placebo-controlled dose- ranging study, examined 146 acutely decompensated heart failure (ADHF) patients with kidney dysfunction. The preliminary data suggest KW-3902 has significant diuretic activity over

The data, presented at the European Hematology Association meeting in Amsterdam, looked retrospectively at 15 patients with chronic or accelerated phase chronic myeloid leukemia (CML) who had received

Ista has invested approximately $8 million for each of the drug candidates which, if approved, will be complementary to Istalol, Ista’s once-daily beta blocker marketed for the treatment